Dataset Information

A snake toxin as a theranostic agent for the type 2 vasopressin receptor.

ABSTRACT: Rationale: MQ1, a snake toxin which targets with high nanomolar affinity and absolute selectivity for the type 2 vasopressin receptor (V2R), is a drug candidate for renal diseases and a molecular probe for imaging cells or organs expressing V2R. Methods: MQ1's pharmacological properties were characterized and applied to a rat model of hyponatremia. Its PK/PD parameters were determined as well as its therapeutic index. Fluorescently and radioactively labeled MQ1 were chemically synthesized and associated with moderate loss of affinity. MQ1's dynamic biodistribution was monitored by positron emission tomography. Confocal imaging was used to observe the labeling of three cancer cell lines. Results: The inverse agonist property of MQ1 very efficiently prevented dDAVP-induced hyponatremia in rats with low nanomolar/kg doses and with a very large therapeutic index. PK (plasma MQ1 concentrations) and PD (diuresis) exhibited a parallel biphasic decrease. The dynamic biodistribution showed that MQ1 targets the kidneys and then exhibits a blood and kidney biphasic decrease. Whatever the approach used, we found a T1/2? between 0.9 and 3.8 h and a T1/2? between 25 and 46 h and demonstrated that the kidneys were able to retain MQ1. Finally, the presence of functional V2R expressed at the membrane of cancer cells was, for the first time, demonstrated with a specific fluorescent ligand. Conclusion: As the most selective V2 binder, MQ1 is a new promising drug for aquaresis-related diseases and a molecular probe to visualize in vitro and in vivo V2R expressed physiologically or under pathological conditions.

SUBMITTER: Droctove L

PROVIDER: S-EPMC7545998 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

A snake toxin as a theranostic agent for the type 2 vasopressin receptor.

Droctové Laura L Lancien Manon M Tran Vu Long VL Susset Michaël M Jego Benoit B Theodoro Frederic F Kessler Pascal P Mourier Gilles G Robin Philippe P Diarra Sékou Siramakan SS Palea Stefano S Flahault Adrien A Chorfa Amélia A Corbani Maithé M Llorens-Cortes Catherine C Mouillac Bernard B Mendre Christiane C Pruvost Alain A Servent Denis D Truillet Charles C Gilles Nicolas N

Theranostics 20200918 25

<b>Rationale:</b> MQ1, a snake toxin which targets with high nanomolar affinity and absolute selectivity for the type 2 vasopressin receptor (V2R), is a drug candidate for renal diseases and a molecular probe for imaging cells or organs expressing V2R. <b>Methods:</b> MQ1's pharmacological properties were characterized and applied to a rat model of hyponatremia. Its PK/PD parameters were determined as well as its therapeutic index. Fluorescently and radioactively labeled MQ1 were chemically synt ...[more]

PMID: 33052234

Similar Datasets

Project description:Understanding snake venom proteomes is becoming increasingly important to understand snake venom biology, evolution and especially clinical effects of venoms and approaches to antivenom development. To explore the current state of snake venom proteomics and transcriptomics we investigated venom proteomic methods, associations between methodological and biological variability and the diversity and abundance of protein families. We reviewed available studies on snake venom proteomes from September 2017 to April 2021. This included 81 studies characterising venom proteomes of 79 snake species, providing data on relative toxin abundance for 70 species and toxin diversity (number of different toxins) for 37 species. Methodologies utilised in these studies were summarised and compared. Several comparative studies showed that preliminary decomplexation of crude venom by chromatography leads to increased protein identification, as does the use of transcriptomics. Combining different methodological strategies in venomic approaches appears to maximize proteome coverage. 48% of studies used the RP-HPLC →1D SDS-PAGE →in-gel trypsin digestion → ESI -LC-MS/MS pathway. Protein quantification by MS1-based spectral intensity was used twice as commonly as MS2-based spectral counting (33-15 studies). Total toxin diversity was 25-225 toxins/species, with a median of 48. The relative mean abundance of the four dominant protein families was for elapids; 3FTx-52%, PLA2-27%, SVMP-2.8%, and SVSP-0.1%, and for vipers: 3FTx-0.5%, PLA2-24%, SVMP-27%, and SVSP-12%. Viper venoms were compositionally more complex than elapid venoms in terms of number of protein families making up most of the venom, in contrast, elapid venoms were made up of fewer, but more toxin diverse, protein families. No relationship was observed between relative toxin diversity and abundance. For equivalent comparisons to be made between studies, there is a need to clarify the differences between methodological approaches and for acceptance of a standardised protein classification, nomenclature and reporting procedure. Correctly measuring and comparing toxin diversity and abundance is essential for understanding biological, clinical and evolutionary implications of snake venom composition.

Dataset Information

A snake toxin as a theranostic agent for the type 2 vasopressin receptor.

Publications

A snake toxin as a theranostic agent for the type 2 vasopressin receptor.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets